These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30280846)

  • 1. [THE USE OF REMAXOL IN THE TREATMENT OF METABOLIC SYNDROME IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND DIABETES MELLITUS 2 TYPE].
    Dudorenko SV; Kovalenko AL; Prokopenko SM; Belogurova EV
    Eksp Klin Gastroenterol; 2016; (6):89-94. PubMed ID: 30280846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis].
    Semiserin VA; Karakozov AG; Malkuta MA; Zolotareva LA; Levchenko OB; Kalyagin IE; Eremin MN
    Ter Arkh; 2016; 88(2):58-63. PubMed ID: 27030185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy].
    Stel'makh VV; Kozlov VK
    Ter Arkh; 2013; 85(4):71-6. PubMed ID: 23808297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EFFECTIVENESS OF CYTOFLAVIN FOR THE CORRECTION OF COGNITIVE IMPAIRMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS].
    Gatskikh IV; Veselova OF; Brikman IN; Shalda TP; Varygina EL; Kuznetsov MN; Shul'min AV; Petrova MM
    Eksp Klin Farmakol; 2015; 78(11):21-5. PubMed ID: 27017701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogenetic therapy of metabolic syndrome at the stage of visceral lesions].
    Stel'makh VV; Kozlov VK; Radchenko VG; Nekrasova AS
    Klin Med (Mosk); 2012; 90(6):61-5. PubMed ID: 22997724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prospects for the application of the natural and preformed therapeutic factors in the treatment of non-alcoholic fatty liver disease].
    Zabolotnaya IB
    Vopr Kurortol Fizioter Lech Fiz Kult; 2016; 93(4):42-48. PubMed ID: 27500678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [INSULIN-LIKE GROWTH FACTOR-1: THE INFLUENCE ON THE LIVER FUNCTION AND RELATIONSHIPS WITH RESISTIN IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND ITS COMBINATION WITH TYPE 2 DIABETES MELLITUS].
    Zhuravlyova LV; Ogneva EV; Zhuravlyova AK
    Eksp Klin Gastroenterol; 2015; (11):23-7. PubMed ID: 27214983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the effect of remaxol on hepatocytes in non-alcoholic fatty liver dystrophy modeling in laboratory C57BL/6 mice].
    Pritulina YG; Prokopenko SE; Kordenko AA; Atiakshin DA; Lobanov VL
    Arkh Patol; 2019; 81(5):64-69. PubMed ID: 31626206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.
    Petta S; Eslam M; Valenti L; Bugianesi E; Barbara M; Cammà C; Porzio M; Rosso C; Fargion S; George J; Craxì A
    Liver Int; 2017 Sep; 37(9):1389-1396. PubMed ID: 28235154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage].
    Bokhan NA; Abolonin AF; Ankudinova IÉ; Kurgak DI; Mandel' AI
    Ter Arkh; 2012; 84(10):51-5. PubMed ID: 23227501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PATOGENETIC VALUE OF VIOLATIONS FROM GLUTATHIONE SYSTEM AT THE PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS ON A BACKGROUND OF DIABETES MELLITUS TYPE II].
    Kostev IV; Teryoshin VA; Sotckaya YA; Homutyanskay NI; Dolgopolova EV; Salamech KA
    Lik Sprava; 2015; (3-4):57-61. PubMed ID: 26827440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative evaluation of clinical efficacy of drugs remaxol and ademetionine in patients with acute ethanol poisoning complicated by the toxic damage of the liver].
    Shilov VV; Shikalova IA; Batotsyrenov BV; Andrianov AIu; Vasil'ev SA; Loladze AT
    Georgian Med News; 2012 Apr; (205):38-43. PubMed ID: 22665730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy of remaxol addition in the treatment of alcohol withdrawal syndrome].
    Vinnikova MA; Utkin SI; Nenasteva AY; Zakharov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(1):40-46. PubMed ID: 26977624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EXPERIENCE IN USE OF HEPATOPROTECTOR REMAXOL FOR TREATING LIVER CIRRHOSIS].
    Gridchik IE; Kurdyakov AV; Matveev AI
    Eksp Klin Farmakol; 2015; 78(12):11-4. PubMed ID: 27051921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice.
    Watanabe S; Takahashi T; Ogawa H; Uehara H; Tsunematsu T; Baba H; Morimoto Y; Tsuneyama K
    Metab Syndr Relat Disord; 2017 May; 15(4):170-177. PubMed ID: 28358620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
    Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
    Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome.
    Kravchenko L; Unhurian L; Tiuzhinska SK; Ivanova Y; Obrazenko M; Zahorodnya L; Yamilova T
    Ceska Slov Farm; 2024; 72(6):297-303. PubMed ID: 38346907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of Remaxol on the efficiency of standard treatment for infiltrative pulmonary tuberculosis].
    Volchegorsky IA; Novoselov PN; Ushkareva EV
    Ter Arkh; 2016; 88(3):73-78. PubMed ID: 27030334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EFFECTS OF MELATONIN ON THE ACONITATE HYDRATASE ACTIVITY, CONTENT OF LIPID PEROXIDATION PRODUCTS AND SOME NON-ENZYMATIC ANTIOXIDANTS IN THE BLOOD OF PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED BY STEATOHEPATITIS].
    Popov SS; Pashkov AN; Shul'gin KK
    Eksp Klin Farmakol; 2015; 78(12):6-10. PubMed ID: 27051920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.